SIRT1-mediated deacetylation of NF-κB inhibits the MLCK/MLC2 pathway and the expression of ET-1, thus alleviating the development of coronary artery spasm
Related Experiment Video
Updated: Dec 4, 2025

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Bo-Wen Wu1,2, Mi-Shan Wu2,3, Yu Liu1,2
1Department of Biochemistry, Basic Medicine College, Hebei University of Chinese Medicine, Shijiazhuang, People's Republic of China.
Abstract:
Coronary artery spasm (CAS) is an intense vasoconstriction of coronary arteries that causes total or subtotal vessel occlusion. The cardioprotective effect of sirtuin-1 (SIRT1) has been extensively highlighted in coronary artery diseases. The aims within this study include the investigation of the molecular mechanism by which SIRT1 alleviates CAS. SIRT1 expression was first determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blot analysis in an endothelin-1 (ET-1)-induced rat CAS model. Interaction among SIRT1, nuclear factor-kappaB (NF-κB), myosin light chain kinase/myosin light chain-2 (MLCK/MLC2), and ET-1 was analyzed using luciferase reporter assay, RT-qPCR, and Western blot analysis. After ectopic expression and depletion experiments in vascular smooth muscle cells (VSMCs), contraction and proliferation of VSMCs and expression of contraction-related proteins (α-SMA, calponin, and SM22α) were measured by collagen gel contraction, 5-ethynyl-2'-deoxyuridine (EdU) assay, RT-qPCR, and Western blot analysis. The obtained results showed that SIRT1 expression was reduced in rat CAS models. However, overexpression of SIRT1 inhibited the contraction and proliferation of VSMCs in vitro. Mechanistic investigation indicated that SIRT1 inhibited NF-κB expression through deacetylation. Moreover, NF-κB could activate the MLCK/MLC2 pathway and upregulate ET-1 expression by binding to their promoter regions, thus inducing VSMC contraction and proliferation in vitro. In vivo experimental results also revealed that SIRT1 alleviated CAS through regulation of the NF-κB/MLCK/MLC2/ET-1 signaling axis. Collectively, our data suggested that SIRT1 could mediate the deacetylation of NF-κB, disrupt the MLCK/MLC2 pathway, and inhibit the expression of ET-1 to relieve CAS, providing a theoretical basis for the prospect of CAS treatment and prevention.NEW & NOTEWORTHY Rat coronary artery spasm models exhibit reduced expression of SIRT1. Overexpression of SIRT1 inhibits contraction and proliferation of VSMCs. SIRT1 inhibits NF-κB through deacetylation to modulate VSMC contraction and proliferation. NF-κB activates the MLCK/MLC2 pathway. NF-κB upregulates ET-1 to modulate VSMC contraction and proliferation.
Insights
Sirtuin-1 (SIRT1) alleviates coronary artery spasm (CAS) by inhibiting vascular smooth muscle cell proliferation and contraction. SIRT1 deacetylates NF-κB, disrupting the MLCK/MLC2 pathway and reducing ET-1 expression to prevent CAS.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Cellular Physiology
Background:
- Coronary artery spasm (CAS) involves intense vasoconstriction causing vessel occlusion.
- Sirtuin-1 (SIRT1) demonstrates cardioprotective effects in coronary artery disease.
- The precise molecular mechanisms of SIRT1 in alleviating CAS require further elucidation.
Purpose of the Study:
- To investigate the molecular mechanism by which SIRT1 alleviates CAS.
- To determine the role of SIRT1 in regulating vascular smooth muscle cell (VSMC) function in CAS.
- To explore the signaling pathways modulated by SIRT1 in CAS.
Main Methods:
- Established an endothelin-1 (ET-1)-induced rat CAS model.
- Quantified SIRT1 expression using RT-qPCR and Western blot.
- Analyzed molecular interactions via luciferase reporter assays, RT-qPCR, and Western blot.
- Assessed VSMC contraction, proliferation, and protein expression following SIRT1 manipulation in vitro.
Main Results:
- SIRT1 expression was significantly reduced in rat CAS models.
- Overexpression of SIRT1 inhibited VSMC contraction and proliferation in vitro.
- SIRT1 inhibited nuclear factor-kappaB (NF-κB) expression via deacetylation.
- NF-κB activation of the myosin light chain kinase/myosin light chain-2 (MLCK/MLC2) pathway and ET-1 upregulation were identified as key mechanisms.
Conclusions:
- SIRT1 alleviates CAS by deacetylating NF-κB, thereby inhibiting the NF-κB/MLCK/MLC2/ET-1 signaling axis.
- This mechanism reduces VSMC contraction and proliferation, offering a potential therapeutic target for CAS.
- SIRT1's role in modulating VSMC function provides a theoretical basis for CAS treatment and prevention strategies.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Nitric Oxide Signaling Pathway
Atherosclerosis I: Introduction

